Astellas starts a second pivotal degrader trial
The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
New prostate cancer hopes from Roche and Novartis
GDC-1261 and INR731 enter phase 1, but how do they act?
Merck makes a new move in Astra battle
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
Roche’s phase 1 mystery
Could RO7851624, newly into clinical trials, be RG6735?
FDA red and green lights: April 2026
Full US approval of Gilead’s Tecartus was the only positive decision last month.
The month ahead: May’s upcoming events
ASCO looms, while FDA decisions are due on Enhertu and Inqovi.
New clinical projects from Kumquat and Context
The two companies have been involved in recent licensing deals.
